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Abstract
Background Accurate information on the facility costs of
treatment is essential to enhance decision making and
funding for malaria control.
Objective The objective of this study was to estimate the
costs of providing treatment for uncomplicated malaria
through a public health facility in Nigeria.
Methods Hospital costs were estimated from a provider
perspective, applying a standard costing procedure. Capital
and recurrent expenditures were estimated using an ingre-
dient approach combined with step-down methodology.
Costs attributable to malaria treatment were calculated
based on the proportion of malaria cases to total outpatient
visits. The costs were calculated in local currency [Naira
(N)] and converted to US dollars at the 2013 exchange rate.
Results Total annual costs of N28.723 million
(US$182,953.65) were spent by the facility on the treat-
ment of uncomplicated malaria, at a rate of US$31.49 per
case, representing approximately 25% of the hospital’s
total expenditure in the study year. Personnel accounted for
over 82.5% of total expenditure, followed by antimalarial
medicines at 6.6%. More than 45% of outpatients visits
were for uncomplicated malaria. Changes in personnel
costs, drug prices and malaria prevalence significantly
impacted on the study results, indicating the need for
improved efficiency in the use of hospital resources.
Conclusion Malaria treatment currently consumes a con-
siderable amount of resources in the facility, driven mainly
by personnel cost and a high proportion of malaria cases.
There is scope for enhanced efficiency to prevent waste and
reduce costs to the provider and ultimately the consumer.
Key Points for Decision Makers
Treatment of uncomplicated malaria consumed up to
25% of a public health facility’s annual budget, with
personnel accounting for a considerable proportion of
the total expenditure for uncomplicated malaria alone.
Nearly half of outpatient visits to the facility were
treated for uncomplicated malaria, necessitating
attention regarding appropriate management for
enhanced efficiency.
A high incidence of presumptive diagnosis and
treatment contributed significantly to the high
treatment costs in the facility.
Overall, there is scope for enhanced efficiency in the
utilisation of the facility resources, especially as it
relates to personnel.
The high cost estimates emphasize the considerable
economic burden of malaria in Nigeria, underscoring
the need for continued donor support for effective
malaria control in the country.
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1 Background
The burden of malaria is highest among tropical regions of
the world, including Nigeria [1]. The disease is a major
public health concern in sub-Saharan Africa (SSA) as it is a
leading cause of avoidable disability and death, especially
among children [2]. This is particularly the case in Nigeria,
which is said to account for a quarter of the burden of
malaria in Africa [3, 4]. Ascertaining health system costs of
treating malaria provides relevant information for soliciting
appropriate funding for its control, from both government
and non-government organisations, to reduce any out-of-
pocket expenditure among patients. Healthcare facilities
are central to the provision of malaria treatment and hence
critical to the success of its management. The provider cost
and quality of services in these facilities have implications
on healthcare utilisation as poor services and high costs of
care can deter utilisation, whether government funded or
out-of-pocket, and promote the use of less effective care or
practices [2, 5]. The success of malaria treatment depends
significantly on the interaction of patients and households
with health services and their costs [2, 5]. The high cost of
care has been identified as a major barrier to access
effective malaria treatment, driving patients to seek care
from less effective sources [6–9]. This presents an equity
issue since the poor, who are often the most affected [6], do
not have access to effective treatments, especially with
currently high out-of-pocket expenditures in Nigeria [10].
In the context of limited resources, weak health systems
and the burden of communicable diseases, particularly in
SSA [11], accurate information on the overall cost of
treatment is essential to improve strategies for malaria
control. Previous studies have reported the economic bur-
den of malaria, particularly to households in SSA
[9, 12–19]. Household costs represent both direct and
indirect costs of treatment and care to patients and care-
givers [18].
Whilst considerable attention has focused on household
costs of malaria treatment [19], information regarding
facility costs has not been adequately explored. Studies that
focused on the cost of treating the disease in hospitals or
health facilities are currently limited [20]. Moreover, such
studies lack sufficient details to enhance decision making.
A study in Nigeria by Onwujekwe et al. [18] recently
estimated a recurrent provider cost per case of malaria
treatment of between US$30.42 and US$48.02 for each
outpatient and inpatient case, respectively, while non-re-
current provider costs per case were put at US$133.07 and
US$1857.15 for outpatient and inpatient care, respectively.
Similarly, Sicuri et al. [19] estimated the health system
costs per case of paediatric inpatient and outpatient malaria
treatment in three countries, Ghana, Tanzania and Kenya,
to be US$2.8–123, US$1.75–48 and US$2.77–57, respec-
tively. Previously in Burkina Faso in 2005, the average
provider cost per patient of paediatric outpatient and
inpatient malaria treatment was estimated at US$6.74 and
US$61.08, respectively [20]. The study in Kenya by
Ayieko et al. [16] estimated providers’ cost of treating
paediatric malaria in district hospitals to be between US$47
and US$75 per case, without distinction between mild and
severe cases. These studies were mostly based on a simple
‘snap-shot’ cost analysis rather than a routine costing
system on which future policy decisions could be based.
Detailed information on the hospital or health facility
cost will provide a more effective tool for decision making
for appropriate resource allocation decisions. This is par-
ticularly important in Nigeria given its high burden of
malaria relative to other African countries and the lack of
comprehensive costing analyses. Consequently, the objec-
tive of this study is to fill this gap and provide adequate
knowledge of the health system costs of malaria treatment
to enable managers to make informed decisions on
resource allocation and efficiency in malaria treatment and
control. This will be achieved by comprehensively evalu-
ating the direct costs of treating uncomplicated malaria at a
public health facility to generate relevant information for
planning and effective implementation of malaria case
management.
2 Methods
2.1 Study Site
The study was carried out at the Nnamdi Azikiwe
University Medical Center (NAUMC), Awka, Nigeria,
which provides primary and secondary healthcare services
to the university community of over 50,000 people, mainly
staff and students. The facility has a capacity of 10–15
beds, with 15 doctors, three pharmacists, 32 nurses and
several other healthcare workers. The workers are appro-
priately trained to provide relevant services. There are both
microscopy and rapid diagnostic test (RDT) tools for lab-
oratory diagnosis and confirmation of malaria parasite.
There are more than 10,000 outpatient visits to the facility
per annum [21].
Health workers are adequately informed on malaria
treatment guidelines and logistics management. Pre-pack-
age artemisinin-based combination therapies (ACTs) are
available for the treatment of uncomplicated malaria. Other
drugs available in the facility include sulphadoxine–pyr-
imethamine (SP) tablets, quinine and artemether injections
for severe malaria and intermittent preventive treatment
(IPT) for women and children. Histidine-rich protein-II
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(HRP-II) RDTs are also available. Patient flow and treat-
ment practices are in line with current treatment guidelines,
as described in a previous study [21].
The supply of antimalarial drugs is carried out using a
procurement guideline. Donors also provide support
through donations of drugs such as the Affordable Medi-
cine Facility—malaria (AMFm) drugs, though quantities
are now relatively small.
Although the availability of antimalarial drugs in the
facility is regular, there are occasions where there is a
limited range of products available as a result of the pur-
chasing procedures, which can affect the choices available
to prescribers. Payments are made by all patients, including
staff, students and community members who access ser-
vices at the centre. Payments for students are deducted
from fees paid in advance.
2.2 Framework and Study Design
A cross-sectional cost-of-illness approach, based on a
standard costing procedure, was employed in this study to
estimate the facility cost of malaria treatment. The costs
were broadly divided into financial and economic costs.
Financial costs represent direct expenditures on resource
procurement, while economic costs are the financial costs
in addition to the opportunity costs of resource utilisation.
These include the costs of donated items, volunteer ser-
vices and the adjustment of financial costs through annu-
alisation of capital items, as well as quantification and
valuation of all resource inputs (including donated items)
utilised in the intervention.
The costs were subsequently categorised into recurrent
and capital expenditures. Capital costs include those items
whose useful life is considered to be longer than 1 year.
Recurrent costs are those costs that lasted for less than
1 year or if payments for them were made more than once a
year, such as the cost of training. The framework is illus-
trated graphically in Fig. 1. Since the medical centre
operates mainly as a primary healthcare facility (services
are basically outpatient), the costing approach involved a
full costing activity for estimating outpatient costs. The
approach uses detailed cost and healthcare utilisation data,
so the costs of all activities in the facility were estimated,
divided into capital and recurrent items.
2.3 Cost Data Identification and Collection
Cost resources were collected and analysed from the per-
spective of the healthcare provider. Consequently, only
direct medical and non-medical costs of malaria treatment
were collected, and not indirect costs such as loss of pro-
ductivity. This is in line with previous costing studies for
the treatment of malaria [18–20], as well as budget impact
analyses [22] and key criteria typically used by health
authorities to value and fund medicines [23].
An ingredient approach was used to identify and collect
all resources used up in the delivery of malaria treatment,
collecting actual line item expenditure and activity data
wherever possible. Top-down calculations were performed
to allocate capital resources where detailed information
was not possible or available.
The baseline data on hospital resource use for malaria
treatment were collected from medical records and phar-
macy departments for patients treated for uncomplicated
malaria between the months of January and June 2013. A
pharmacy research assistance was engaged and trained to
collect and document all patient-related encounters at the
facility’s dispensing units, using a prepared notebook for
collecting and documenting relevant variables per patient
including the date, age, sex, diagnosis for malaria and co-
morbidity as well as the costs of all medications and sup-
plies dispensed. Patient records were comprehensively
reviewed to obtain information on the level of resource use
per patient. Resource use data included the overall costs of
medication (including the type, frequency, amount, dura-
tion and route of administration of medications), supplies
and laboratory tests. Pharmacy prices were based on cur-
rent published prices at the time [24]. We have previously
used comprehensive patient records to assess adherence to
current treatment guidelines [21].
Other resource items included the costs of staff/per-
sonnel, building, equipment, utilities and other sundry
expenses. Utilities and overheads include administrative
costs, office maintenance, water and electricity bills, tele-
phone, fax and postage. Supplies comprised office sta-
tionery and other consumables. Vehicle maintenance and
transport are included in the fuel/maintenance costs. A
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Fig. 1 Components of the health facility cost of malaria treatment
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detailed list of items collected and measured, and their
source, is shown in Table 1.
Expenditure data were collected from the bursary/ac-
counts and stores/maintenance departments. Budget data
were also used to estimate expenditure where other sources
were not available. In-depth interviews were held with the
chief medical director, chief nursing officer, chief phar-
macist and other heads of departments in the facility to
identify the type and number of staff and equipment that
are used in malaria treatment. Non-hospital costs, such as
patients’ costs/contributions in terms of payment for
medicines supplied and travel, were not collected as we
concentrated on facility costs only.
Data collected were then double entered into a Microsoft
Excel (Microsoft Corp., Redmond, WA, USA) spread-
sheet and checked for consistency. Discrepancies were
identified and resolved while referencing the original data
forms. The costs data were analysed at the 2013 price level.
2.4 Cost Calculations
All costs were measured at their market values in local
Nigerian currency [Naira (N)] and converted to US dollars
at the 2013 exchange rate (N157 = $US1). This rate
reflected the period of study. Any update to current values
may not reflect the true costs given the current challenges
of the Nigerian economy, unstable prices and unrealistic
exchange rates, which will affect the analysis. Conse-
quently, we have kept to the 2013 exchange rate.
Capital costs were measured and valued by first
annuitising the initial market price of the capital items over
their expected useful life and then adding them to the
annual recurrent estimated costs. This reflects the value-in-
use of the capital assets. Vehicles and equipment costs
were annualised over a 10-year period and discounted at
3% in line with previous publications [25, 26]. Capital
items were divided into building (30% annualisation) and
equipment, such as cabinets, furniture, stethoscopes, ther-
mometers, motor vehicles (ambulances), and discounted
[9, 26, 27].
The effect of variation of discount rates was examined
in the sensitivity analysis. Building costs were estimated
from office floor spaces, measured and valued on the
basis of a standard cost per square meter land valuation
measurement, and annualised over a useful 30-year period
at a 3% discount rate [28]. Allocation of shared costs in
joint offices was based on the proportion of malaria
treatment.
Personnel costs were valued according to existing
annual staff gross salary scales, including benefits and
allowances. Time spent by each staff category in malaria
treatment or on a suspected malaria case is multiplied by
the pro rata earnings for each category. Given the variation
of staff time per patient, which presents challenges when
estimated on patient-specific basis, the time item was
included in the outpatient visit cost.
Direct medical and non-medical costs of supplies and
consumables were calculated by summing their used
quantities within the period, multiplied by their individual
or replacement costs. Actual purchase prices for resources
were used for estimating unit costs. This included the
pharmacy purchase price for medicines. For items whose
prices were not available, replacement costs were used.
The costs of shared supplies and utilities were valued using
a step-down approach and allocated on the basis of facility
utilisation of malaria patients [28]. However, for resources
unique to malaria treatment, such as laboratory diagnosis,
full allocations were made based on the actual malaria
service utilisation. Medication costs per patient were cal-
culated by multiplying the quantities of drugs prescribed/
dispensed by the prices obtained from the pharmacy
department [24].
Table 1 Cost items and
sources of collection
Item Source
Capital items
Building/space Maintenance
Vehicles Stores
Furniture/equipment Stores
Medical devices (e.g. stethoscopes, surgical instruments) Departments
Non-medical devices (e.g. furniture, televisions and air conditioners) Departments/stores
Recurrent costs
Drugs procurement costs Pharmacy
Personnel Administration
Training/capacity building Administration
Utilities/overhead Administration
Fuel/maintenance Maintenance
Supplies/office costs Stores
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Generally, while medicines and laboratory examinations
were treated as recurrent, other costs were regarded as
overheads. Their costs were obtained by direct attribution
based on the proportion of treated malaria cases. This was
calculated by multiplying the cost of the overheads with the
proportion of malaria cases treated at the outpatient
department (OPD) in the facility within the study period.
Finally, the total recurrent and capital costs were summed
to estimate the total annual cost associated with malaria
treatment. The malaria treatment cost per patient was
obtained by dividing the facility’s total annual cost of
malaria treatment by the total number of malaria cases over
the study period.
This study estimated the costs of outpatient treatment for
uncomplicated malaria, where ‘uncomplicated malaria’ is
defined as including all malaria cases where no hospitali-
sation is required.
2.5 Assumptions
A number of assumptions were made to inform the cost
calculations. These are shown in Table 2.
2.6 Sensitivity Analysis
A sensitivity analysis was performed to test the robustness
of the estimated costs. The following parameters were
varied:
• Discount rate: 3–5%
• Staff salaries: reduced by 50%
• Malaria prevalence: 0.47–0.27
• Change in drug costs from actual purchase prices.
Personnel/staff salary was chosen as a key parameter for
the sensitivity analysis as this is a major cost driver. Salary
staff costs are known to be lower in primary healthcare
centres in Nigeria, where malaria is mostly treated [18];
hence, the sensitivity analysis included a 50% reduction.
The choice of 0.27 prevalence was used to reflect the rate
obtained in a larger two-facility-based study previously
reported [21], as well as a measure of accuracy given the
prevalence of presumptive treatment in the health facility
as 43% of the treated cases do not actually have malaria.
Similarly, drug prices are also a known variable parameter.
2.7 Data Analysis
The data were analysed for financial and economic costs.
Further analysis was carried out for costs without co-
medication (using only antimalarial drugs) and with co-
medication. Data were managed and analysed using
Microsoft Excel (version 2007) as well as Statistical
Package for Social Sciences (SPSS) version 16 (SPSS
Inc., Chicago, IL, USA) and GraphPad Prism 5 (GraphPad
Software, La Jolla, CA, USA). The costs data were cal-
culated and presented as means and medians.
2.8 Ethics Approval and Consent to Participate
Although this study did not involve patients’ participation,
ethical approval was sought and obtained from the Nnamdi
Azikiwe University Teaching Hospital Ethical Review
Committee as part of a larger study on the cost-effective-
ness analysis of antimalarial drugs in south east Nigeria
(Reference NAUTH/CS/66/62).
3 Results
3.1 Financial and Economic Cost Estimates
Distribution of the financial and economic costs of malaria
treatment at the facility during the study period is shown in
Table 3.
Table 3 shows a total annual financial cost of
N33,533,217.86 (US$213,587.37) for treating patients with
malaria in this facility. The total annual economic cost was
estimated at N28,723,723.15 (US$182,953.65), comprising
98.2% recurrent and 1.8% capital items.
Major cost drivers included personnel at 82.5% of total
costs, followed by antimalarial medicines at 6.6%
(Table 3). Overhead costs (represented by the costs of
administration and utilities) contributed N1,040,357, rep-
resenting 3.6% of the total cost of malaria treatment. Based
on the number of malaria cases treated during the study
period, this translated into an average of N4,943.84
(US$31.49) per outpatient episode of uncomplicated
malaria without co-medication. With co-medication, the
average unit cost increased to N5522.29 (US$35.63) per
Table 2 Assumptions used in
the cost calculations
Parameter Assumption Source
Discount rate 3% Central Bank of Nigeria (CBN) interest rate
Personnel costs Staff gross earnings Finance/audit department
Exchange rate N157 = US$1 Nigerian foreign exchange rate—2013
Malaria prevalence 0.47 (sensitivity analysis 0.27) Hospital records (university-wide data)
N Nigerian Naira
Cost of Malaria Treatment
uncomplicated malaria episode. Figure 2 shows the relative
composition of the annual economic costs of treatment for
uncomplicated malaria in the facility.
3.2 Drug Treatment Costs
Antimalarial drug treatment amounted to a total economic
cost of N1,906,197 (US$12,141.38) per annum at N328
(US$2.08) per case, representing 6.6% of the total cost
(Table 3). When the cost of co-medication is included, the
total increased to N5,266,968 per annum at N906
(US$5.77) per case, representing 16.4% of the total cost.
3.3 Sensitivity Analysis
The results of sensitivity analyses are presented in Table 4.
The unit cost of treatment changed by 37% when a malaria
prevalence rate of 0.27 was used in place of the hospital
rate of 0.47. This reflects the measure of accuracy,
assuming that 43% of the treated cases do not actually have
malaria. As mentioned, the revised rate was used to reflect
the value obtained in a previous study [21] and as a mea-
sure of accuracy given the high rate of presumptive treat-
ment in the facility. Reducing the personnel cost by 25%
and 50%, respectively (to compare with other non-uni-
versity health facilities), showed a significant drop in the
total and unit values by 21 and 41%, respectively. Changes
in the discount rate and drug prices did not significantly
impact on the treatment costs.
4 Discussion
The findings suggest that the medical centre generated a
total annual economic cost of N28,723,723.15
(US$182,954) for the treatment of uncomplicated malaria
during the study period (Table 3), comprising both recur-
rent and capital expenditures. Personnel accounted for a
considerable proportion at 82.5% of total costs, followed
by antimalarial drugs at 6.6%. This translates to an average
provider cost of N4943 (US$31.49) for treating one epi-
sode of uncomplicated malaria in the OPD, with anti-
malarial drugs. When the cost of co-medication is included,
the average value of treatment increased to N5522.29
(US$35.23) per case. This represents approximately 25%
of total hospital expenditure, indicating a substantial pro-
portion of the facility’s annual budget.
The unit cost estimates in this study fall within the
findings of similar studies reported in a systematic review
by White et al. [17], for both financial and economic costs
of treating uncomplicated malaria from a provider
Table 3 Annual financial and economic costs of malaria treatment (2013 prices)
Items Type of resource Financial cost
(N)
Cost profile
(%)
Economic cost
(N)
Unit cost
(N)
Unit cost
(US$)
Cost profile
(%)
Capital items Buildings/space 2,113,277 6.3 137,475.76 23.66 0.15 0.5
Vehicle 3,209,894 9.6 376,200.56 64.75 0.41 1.3
Medical devices 0.00 0.0 0.00 0.00 0.00 0.0
Non-medical devices 0.00 0.0 0.00 0.00 0.00 0.0
Subtotal 5,323,171.04 15.9 513,676.32 88.41 0.56 1.8
Recurrent
items
Personnel 23,684,380 70.6 23,684,380 4076.49 25.96 82.5
Utilities 1,040,357 3.1 1,040,357 179.06 1.14 3.6
Drugs 1,906,197 5.7 1,906,197 328.09 2.09 6.6
Medical supplies and
consumables
1,188,980 3.5 1,188,980 204.64 1.30 4.1
Laboratory 390,134 1.2 390,134 67.15 0.43 1.4
Subtotal 28,210,047 84.1 28,210,047 4855.43 30.93 98.2
Total cost 33,533,218 100 28,723,723 4943.84 31.49 100
Currency conversion rate: US$1.00 = N157
N Nigerian Naira
Fig. 2 Composition of the facility annual economic costs of malaria
treatment
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perspective. The economic cost ranged between US$9.14
and US$37.99 per episode of uncomplicated malaria at a
median cost US$22.48. The study in Nigeria by Onwu-
jekwe et al. [18], undertaken in selected public primary
health facilities in a rural setting, estimated a provider cost
of US$30 per outpatient malaria treatment. However, this
estimate represents only the recurrent component and did
not include the cost of capital items, reported to be US$133
per case. The unit cost estimates are also comparable with
those of a previous study in South Africa [29], which
estimated a hospital cost of outpatient malaria treatment at
between US$28.55 (baseline) and US$37.99 (post-inter-
vention with ACT) per case. Similarly, a study in India by
Gogtay et al. [27] estimated a hospital treatment cost of
between US$15.64 and US31.87 per outpatient malaria
treatment. Similar to our study, these were hospital-level
cost studies.
Similar provider cost estimates in other African coun-
tries suggest a range of US$3–6 per case of uncomplicated
malaria [19], indicating considerable differences to this
study. However, these studies did not report comprehensive
analysis of the provider cost of malaria treatment, making
comparisons difficult. These reports also typically repre-
sented a ‘snap shot’ analysis of provider cost data [20].
Consequently, from a more comprehensive approach, our
study results suggest appreciably higher unit and total cost
estimates for uncomplicated malaria treatment, with a
higher rate of malaria prevalence, than in previous studies.
Other studies have been conducted in health centres,
which typically represent lower-level health facilities and
therefore have less expensive services than hospital-level
facilities in which health workers receive higher salaries.
As mentioned, hospital services are expected to cost more
than twice those of health centres, mainly due to higher
personnel and capital unit costs [29]. In this study, per-
sonnel cost averaged US$26 per case of uncomplicated
malaria. This is considerably higher than the unit cost of
US$3.98 reported by Wiseman et al. [9] in Tanzania, but
close to the value of US$24.00 documented in the study by
Onwujekwe et al. [18], which was carried out in health
centres in Nigeria.
In this study, a baseline malaria prevalence rate of 0.47
was used for the analysis, based on the proportion of
malaria treatment in the facility. This is significantly higher
than values used in previous studies, which ranged between
0.15 and 0.23 [25, 28]. These studies assumed malaria
prevalence rates in the study settings rather than the facility
rate as used in this study. The high proportion of malaria
treatment in this study may reflect the malaria prevalence
and high transmission rate in this area in Nigeria. However,
the high incidence of presumptive malaria treatment
reported in the centre [21], increases the incidence of
malaria treatment, thereby overstating malaria prevalence.
This suggests overtreatment and wastage, significantly
contributing to the increased cost of care. When the
prevalence rate was reduced by 43% to 0.27 in the sensi-
tivity analysis, the unit cost estimate significantly dropped
by 37% to approximately US$19.84 per case (Table 4).
Consequently, to reduce costs and prevent waste, there is a
clear need to improve the accuracy of treatment through
effective laboratory confirmation of malaria cases, using
microscopy or RDT. Laboratory diagnosis has been
demonstrated to be cost effective [30, 31]. The limited use
laboratory diagnosis in this study is reflected in the low
proportion of laboratory costs to the total cost of treatment
(Table 3).
Table 4 Sensitivity analysis of uncertain parameters on the study results
Parameter Percentage change in
parameter
Effect on treatment costs Comments/justification
Malaria
prevalence
43% reduction in the rate
used from 0.47 to 0.27
Total and average costs
significantly reduced by 37%
Indicates the significant impact of accuracy of diagnosis on the cost
of treatment
Change in rate to reflect the lower prevalence in a previous larger
study as well as capture the impact of presumptive treatment
Personnel
salaries
25% reduction in
personnel cost
Treatment costs (total and
average) reduced by 21%
High cost of personnel indicates significant contribution to the high
costs of treatment
50% reduction in
personnel cost
Treatment costs reduced by
41%
Discount
rate
3–5% No significant change in
treatment costs
Discount rate shows no impact on treatment costs
Reflects standard practice in economic evaluations [26]
3–10% No significant change in
treatment costs
Drug costs Increased by 25% Total and average cost per case
increased minimally at 2%
Drug prices do not significantly impact on the total cost of
treatment
Decreased by 25% Total and cost per case reduced
minimally at 3.3%
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Furthermore, the high unit cost of this study may also
suggest low capacity or under-utilisation of available
resources, based on the number of patient visits, or alterna-
tively due to disproportionate use of personnel resources.
Either way, this indicates inefficiency of resource utilisation.
Strengthening the healthcare system through efficient utili-
sation of resourceswillmake it functionmore effectively and
reduce overall costs to the provider and patients [18].
Medicines were the other significant contributors to
treatment cost (Table 3). The current use of ACT, which is
considerablymore expensive thanmonotherapy, would have
contributed to the increased cost of care [32, 33]. The com-
paratively high cost of treatment could be reduced through a
more efficient approach to malaria treatment. This could
include reducing the extent of presumptive diagnoses with
associated treatment to increase the accuracy of diagnosis
and associated treatment, thereby reducing waste.
This provider cost of treatment has implications on the
burden of malaria treatment to the patient or households
through cost transfers as professional fees. When viewed
against the need to recover costs, especially fromprivate health
facilities, this cost is transferred to the patient in the form of
hospital charges and/or professional fees, thereby increasing
patients’ out-of-pocket expenses. Added to the indirect cost of
productivity loss, the overall cost would increase beyond the
capacity of many low-income patients, considering that
majority of the population in Nigeria live below the poverty
line [34]. This should be avoided where possible.
Onwujekwe et al. [18] reported household expendi-
tures/cost of US$12.57 and US$23.20 for outpatients and
inpatients, respectively. A high facility cost of treatment
contributes to making patients seek alternative sources of
care for malaria treatment [6, 7], with implications for the
subsequent quality of care. When viewed against similar
costs and the economic status of the population, this cost
represents a significant proportion of gross domestic pro-
duct (GDP) in low-income settings. However, unlike in the
private health facilities where there is expected to be full
cost recovery, health services are highly subsidised in
public health facilities in Nigeria, leading to limited cost
recovery measures [34] benefitting patients. This may
explain why an increasing proportion of patients seek care
in public facilities.
Further recognition of the burden of malaria in low-
income settings such as those that can occur in settings in
Nigeria has made many regions in Nigeria operate free
maternal and child health (FMCH) services for a package
of services including malaria treatments [18, 24]. This
implies that the provider bears a significant proportion of
malaria treatment [18]. This high cost of malaria treatment
underscores the need for donor support in the provision of
malaria treatment services to improve patient care, and it is
hoped this will continue. Robust information regarding
current costs of treatment can benefit such groups in their
deliberations as well as payers of healthcare in general
[22, 35].
Generally, the cost of malaria treatment (comprising
household and/or health system costs) is high in Nigeria
(Table 3) and other low-income settings where malaria is
prevalent. The proportion of who pays for the treatment
varies between the health system and the household,
depending on the context. This can be catastrophic to some
households. However, this is not the case in health systems
where providers bear most of the cost of treatment. Even
though Nigeria has recently launched the national health
insurance scheme to provide the necessary buffer to health
expenditure [10], the effect is yet to be felt as the majority
of the citizens still pay out of pocket. The provision of
FMCH services in many regions in Nigeria is commend-
able but there needs to be improvement for long-term
sustainability. On the whole, improved efficiency in the
utilisation of resources will enhance the effectiveness of
the healthcare system and reduce the overall cost to the
provider and consumer. We hope this type of analysis
paves the way for more thorough economic evaluations in
Nigeria to improve the quality, efficiency and sustainability
of the healthcare system in the country. This builds on
recent guidance regarding budget impact analyses [22, 35].
4.1 Study Limitations
We are aware that the study was carried out in one centre,
which may affect generalisability of the estimates. This
was due to the challenges in the availability of reliable data
and in getting permission to collect similar data from other
sites. Consequently, the costs may be overestimates com-
pared with costs in more routine ambulatory care settings.
However, this was allowed for in the sensitivity analysis. In
addition, the findings share many characteristics of similar
studies, which enhance their reliability and generalisability.
We similarly performed sensitivity analyses of key
resource items in order to reflect the potential variability in
key parameters in different settings and facilities in order to
assess their impact on the cost estimates. We acknowledge
that scaling up the study would strengthen the findings, and
this will be the subject of future research projects.
We are aware that we used patient records to help cal-
culate resource use. However, this is a standard source of
patient data within health economic studies. In addition,
this hospital is a university healthcare facility with better
record-keeping practices than other general facilities.
Consequently, we believe patient records to be an accept-
able method to collect reliable data for this study. We have
already used part of the data when reviewing treatment
practices against current guidelines and found it to be
reliable [21].
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We also accept that data on patients’ and household
costs were not included; however, these are not part of
provider costs. Overall, we believe the findings from our
study are robust and provide useful baseline information
for designing future scale-up measures.
Finally, this study used a costing method that evaluated
the cost of treating episodes of uncomplicated malaria
through an outpatient clinic. This suggests the need to
exercise care when comparing the estimates from other
studies due to differences in costing objectives and
methodologies.
5 Conclusion
The study shows that the costs associated with malaria
treatment in this health facility are significant, constituting
a considerable proportion of overall hospital expenditure.
This suggests that the health system in Nigeria currently
bears a significant proportion of malaria treatment costs.
The findings have implications for effective malaria
treatment in view of the transferred cost to the patients,
who are already burdened by the high indirect cost of
productivity loss and out-of-pocket expenses as well as a
healthcare system that is already burdened by the chal-
lenges of limited resources. Our results emphasise the
considerable economic burden of malaria infection in the
country, underscoring the need for continued government
and donor agency support to effectively manage malaria
in Nigeria.
To enhance efficiency in malaria treatment and control,
there is an appreciable need to strengthen the healthcare
system to make it function more effectively and reduce the
overall burden of care on the provider and consumer. The
findings of this study may help provide information to
guide further studies as well as to solicit appropriate
funding allocation for effective malaria control in Nigeria
and other similar settings.
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